Century Therapeutics, Inc’s Post

We look forward to participating in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 10. We're excited to reconnect with the #biotech community and discuss our ongoing work to address significant unmet needs for patients with #autoimmune and #inflammatorydiseases. #iPSC #celltherapy

This past week, team members participated in group spin classes to celebrate #EmployeeHealthAndWellnessMonth. We enjoy organizing events like these that support our colleagues’ well-being and provide a fun opportunity to recharge and connect with each other. 

June is #NationalCancerSurvivorsMonth. At Century, we honor the courage and resilience of all cancer survivors and remain committed to expanding patient access to life-saving cell therapies so that one day all patients with cancer can become survivors. #CelebrateSurvivorship #CancerResearch

Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024

We are looking forward to the American Society of Clinical Oncology (ASCO) Annual Meeting, where we will present interim data from our ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) non-Hodgkin #lymphoma. We hope to see you at #ASCO24!

Century recognizes #LupusAwarenessMonth as part of the community dedicated to supporting those with Systemic Lupus Erythematosus. Recently, we hosted a booth at the LuCIN Community Meeting to further educate on the potential of CNTY-101 in #SLE and our planned CALiPSO-1 trial. 

We’re excited to announce two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting. The preclinical data presented highlights advances in our #iPSC platform technology and programs, including the potential of CNTY-101 to treat B-cell driven #autoimmunediseases such as #SLE. Learn more: https://bit.ly/3QEr4VU #ASGCT2024

Today, we reported financial results and business highlights for Q1 2024. Read the full press release: https://bit.ly/4bcWoTU   #biotech #investors

May is National Cancer Research Month. At Century, we are proud of our work to advance the research and development of next-generation iPSC-derived #celltherapies to provide meaningful treatments for people with #cancer. Learn more about our programs across #hematology, #oncology, and #autoimmune and #inflammatorydiseases: https://bit.ly/3M5EmJw #NCRM24  

We are excited to attend Chardan 's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, where members of our management team will participate in a virtual fireside chat and panel. Learn more: https://bit.ly/49UR8m5     #ipsc #celltherapy